Nectar Lifescience Ltd

NSE: NECLIFE BSE: 532649

₹10.26

+0.12 (1.18%)

Fri, 06 Nov 2026, 07:47 pm

MTF 5xInvest in Nectar Lifescience Ltd with 5x Leverage Buy with MTF

Market Cap (in Cr)199.12

PE Ratio0

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Nectar Lifescience Ratios

D/E EV EV/EBITDA P/B P/CF P/E P/S ROE %

Particulars	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Price to earnings ratio	9.47	6.50	5.59	4.45	8.44	5.20	7.35	4.10	8.74	12.51	15.70	14.25	11.35	8.06	6.98	0	21.53	0	135.20	0
Price to book ratio	1.99	0.97	1.08	0.57	1.31	0.74	0.69	0.40	0.59	0.86	0.89	0.78	0	0.35	0.20	0.39	0.50	0.33	0.63	0.54
Price to sales ratio	1.39	0.68	0.57	0.32	0.93	0.51	0.41	0.22	0.33	0.50	0.51	0.48	0.32	0.14	0.09	0.27	0.32	0.23	0.40	0.31
Price to cash flow ratio	0	45.65	2.78	2.25	0	0	7.20	1.34	4.22	21.39	16.66	8.96	0	3.95	1.37	0	29.83	6.36	4.50	5.35
Enterprise value	498Cr	681Cr	877Cr	905Cr	1351Cr	1299Cr	1556Cr	1224Cr	1391Cr	1718Cr	1777Cr	1654Cr	1538Cr	1265Cr	979Cr	1295Cr	1381Cr	1092Cr	1290Cr	1078Cr
Enterprise value to EBITDA ratio	8.18	8.42	6.92	6.40	6.88	5.80	6.79	4.22	4.83	6.46	7.40	7.32	6.46	4.74	4.41	11.62	8.67	19.84	8.35	0
Debt to equity ratio	0.84	1.91	1.71	2.32	0.97	1.10	1.33	1.01	0.93	0.97	1.01	0.87	0.90	0.82	0.69	0.85	0.79	0.71	0.59	0.61
Return on equity %	28.26	21.69	29.61	18.04	19.98	15.37	9.73	10.38	6.92	7.03	5.67	5.64	5.06	4.40	2.84	-6.67	2.33	-2.25	0.47	-11.23

Nectar Lifescience Ltd Ratios

The Nectar Lifescience Ltd Ratios page provides a complete fundamental analysis of Nectar Lifescience Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Nectar Lifescience Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Nectar Lifescience Ltd (NSE: NECLIFE, BSE: 532649) is currently trading at ₹10.26, with a market capitalization of ₹199.12Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Nectar Lifescience Ltd remains a key stock for fundamental analysis using Nectar Lifescience Ltd Ratios.

Nectar Lifescience Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Nectar Lifescience Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Nectar Lifescience Ltd Ratios.

Historically, the Nectar Lifescience Ltd P/E ratio has shown strong fluctuations:

2025: 0
2024: 135.20
2023: 0
2022: 21.53
2021: 0

The decline in Nectar Lifescience Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Nectar Lifescience Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.54.

Historical P/B trend:

2025: 0.54
2024: 0.63
2023: 0.33
2022: 0.50

Nectar Lifescience Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Nectar Lifescience Ltd P/S ratio currently stands at 0.31, an important part of Nectar Lifescience Ltd Ratios for revenue valuation.

Historical P/S ratio:

2025: 0.31
2024: 0.40
2023: 0.23
2022: 0.32

A stable or declining Nectar Lifescience Ltd P/S ratio indicates cautious market sentiment.

Nectar Lifescience Ltd Price to Cash Flow Ratio (P/CF)

The Nectar Lifescience Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 5.35.

Historical Nectar Lifescience Ltd Price to Cash Flow Ratio:

2025: 5.35
2024: 4.50
2023: 6.36
2022: 29.83
2021: 0

The rising Nectar Lifescience Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Nectar Lifescience Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Nectar Lifescience Ltd EV currently stands at ₹1078Cr, representing the total company valuation including debt.

Historical EV trend:

2025: 1078Cr
2024: 1290Cr
2023: 1092Cr
2022: 1381Cr

Nectar Lifescience Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Nectar Lifescience Ltd EV/EBITDA ratio is currently 0, a key metric in Nectar Lifescience Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

2025: 0
2024: 8.35
2023: 19.84
2022: 8.67

Stable Nectar Lifescience Ltd EV/EBITDA indicates balanced valuation.

Nectar Lifescience Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Nectar Lifescience Ltd D/E ratio is currently 0.61, reflecting leverage and financial stability.

Historical D/E:

2025: 0.61
2024: 0.59
2023: 0.71
2022: 0.79

Nectar Lifescience Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Nectar Lifescience Ltd ROE currently stands at -11.23%, showing profitability and capital efficiency.

Historical ROE:

2025: -11.23
2024: 0.47
2023: -2.25
2022: 2.33

Declining ROE indicates pressure on profitability.

Nectar Lifescience Ltd Ratios Analysis Summary

The Nectar Lifescience Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Nectar Lifescience Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Nectar Lifescience Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.